LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

3.47 -0.86

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.25

Максимум

3.59

Ключови измерители
By Trading Economics
Приходи	-31M -14M
Продажби	-32M 41M
EPS	-0.22
Марж на печалбата	-34.333
Служители	293
EBITDA	-37M -15M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+79.83% upside

Дивиденти
By Dow Jones
Следващи печалби	19.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	65M 188M
Предишно отваряне	4.33
Предишно затваряне	3.47

Настроения в новините

By Acuity

44%

56%

143 / 346 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

1.47 / 1.64 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.05.2026 г., 22:54 ч. UTC

Печалби

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.05.2026 г., 23:17 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13.05.2026 г., 23:16 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13.05.2026 г., 23:15 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13.05.2026 г., 23:14 ч. UTC

Печалби

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13.05.2026 г., 23:02 ч. UTC

Пазарно говорене

Печалби

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13.05.2026 г., 22:59 ч. UTC

Пазарно говорене

Печалби

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13.05.2026 г., 22:24 ч. UTC

Печалби

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13.05.2026 г., 22:23 ч. UTC

Печалби

Xero FY International Organic Revenue Growth 25%>XRO.AU

13.05.2026 г., 22:23 ч. UTC

Печалби

Xero FY International Revenue Growth 47%>XRO.AU

13.05.2026 г., 22:22 ч. UTC

Печалби

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13.05.2026 г., 22:19 ч. UTC

Печалби

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13.05.2026 г., 22:19 ч. UTC

Печалби

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13.05.2026 г., 22:18 ч. UTC

Печалби

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13.05.2026 г., 22:16 ч. UTC

Печалби

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13.05.2026 г., 22:15 ч. UTC

Печалби

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13.05.2026 г., 22:15 ч. UTC

Печалби

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13.05.2026 г., 22:13 ч. UTC

Печалби

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13.05.2026 г., 22:12 ч. UTC

Печалби

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13.05.2026 г., 22:11 ч. UTC

Печалби

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13.05.2026 г., 22:11 ч. UTC

Печалби

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13.05.2026 г., 22:10 ч. UTC

Печалби

Xero Did Not Declare a Dividend>XRO.AU

13.05.2026 г., 22:10 ч. UTC

Печалби

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13.05.2026 г., 22:09 ч. UTC

Печалби

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13.05.2026 г., 22:00 ч. UTC

Печалби

Cisco to Shed Jobs for All-In AI Push -- Update

13.05.2026 г., 21:11 ч. UTC

Печалби

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

79.83% нагоре

12-месечна прогноза

Среден 6.33 USD 79.83%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

143 / 346 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.